Companies · Biotech / Pharma

Boulder Botanicals & Biosciences Laboratories, Inc.

GOLDEN · Biotech / Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on Boulder Botanicals & Biosciences Laboratories, Inc. — recommendation, valuation, rhythm, risks.
$4.7M
Total raised · real
2
Rounds
0.1×
Latest step-up
Top 53%
Sector rank · raised
Series A
Latest stage · inferred · Fri Feb 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Boulder Botanicals & Biosciences Laboratories, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.10× the median modeled value of Series A Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Dormant
  • Last raise 7.4 yr ago; this sector typically re-raises about every 15 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Boulder Botanicals & Biosciences Laboratories, Inc. is one of 227 Biotech / Pharma companies tracked from GOLDEN. By capital raised it ranks mid-pack (ahead of 48% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
25
Investors (latest)
2015
Year incorporated
2019-02-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2018-12-17 Raised $4.2M (real) Modeled valuation $142M (est)$4.2M$142MSeries A2018Series A · 2019-02-15 Raised $500K (real) Modeled valuation $17M (est)$500K$17MSeries A2019+$500KCumulative $4.7M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.2M · 2018
Series A extension$500K · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$16.8M
Base estimate est.
$559K
Conservative case
$91.1M
Upside case
$2.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Series A · modeled $141.8M · 2018-12-172018Series A · modeled $16.8M · 2019-02-152019
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
45%
Survival probability
25% low · 62% high
1.59×/yr
Annual markup
2.01×/yr upside case
6.0 yr
Elapsed time used
7.4 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
2 mo
Avg between rounds
Capital velocity
7.5 yr
On record since
2018
First round
2
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.8× of median
This company$4.7M
Sector median$5.6M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$500K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$16.8M
Sector median$30.5M

Raised more than 48% of sector peers (real $). Modeled value above 41% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #15 of 15.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Advanced Bio Development, Inc. · Series A Raised $28.2M · modeled $435.7M (est)Generian Pharmaceuticals, Inc. · Series A Raised $13.0M · modeled $435.2M (est)Teiko Bio, Inc. · Series A Raised $11.6M · modeled $220.4M (est)Singular Bio, Inc. · Series A Raised $6.6M · modeled $220.3M (est)Genomic Prediction, Inc. · Series A Raised $12.0M · modeled $211.8M (est)Abreos Biosciences, Inc. · Series A Raised $7.5M · modeled $172.7M (est)Fount Bio, Inc. · Series A Raised $8.2M · modeled $171.7M (est)Ascus Biosciences, Inc. · Series A Raised $28.7M · modeled $167.5M (est)Luna Pharmaceuticals, Inc. · Series A Raised $10.5M · modeled $148.8M (est)IpiNovyx Bio, Inc. · Series A Raised $7.0M · modeled $131.4M (est)Archean Biologics, Inc. · Series A Raised $4.5M · modeled $100.7M (est)Brave Bio, Inc. · Series A Raised $5.3M · modeled $99.7M (est)Boulder Botanicals & Biosciences Laboratories, Inc. (this company) Raised $4.7M · modeled $16.8M (est)Boulder Botanicals & Biosciences Laboratories, Inc.
CompanyStageRaised · realValue · estvs peer med.
Advanced Bio Development, Inc.Series A$28.2M$435.7M2.60×
Generian Pharmaceuticals, Inc.Series A$13.0M$435.2M2.60×
Teiko Bio, Inc.Series A$11.6M$220.4M1.32×
Singular Bio, Inc.Series A$6.6M$220.3M1.32×
Genomic Prediction, Inc.Series A$12.0M$211.8M1.26×
Abreos Biosciences, Inc.Series A$7.5M$172.7M1.03×
Fount Bio, Inc.Series A$8.2M$171.7M1.03×
Ascus Biosciences, Inc.Series A$28.7M$167.5M1.00×
Luna Pharmaceuticals, Inc.Series A$10.5M$148.8M0.89×
IpiNovyx Bio, Inc.Series A$7.0M$131.4M0.78×
Archean Biologics, Inc.Series A$4.5M$100.7M0.60×
Brave Bio, Inc.Series A$5.3M$99.7M0.60×
Boulder Botanicals & Biosciences Laboratories, Inc. this companySeries A$4.7M$16.8M0.10×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.2M2018-12-17$19.2M$141.8M90%
Series A$500K2019-02-15$2.3M$16.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.2M2018-12-17
    • First recorded raise — entered as Series A.
    • 66 investors on this round.
  2. Series A$500K2019-02-15
    • Came back fast: 2 mo vs the ~15 mo sector norm.
    • Round 8.5× smaller than the prior — bridge or down round.
    • 25 investors on this round.
Intelligence
2019 ~Q2
Modeled next raise · ~2mo cadence
$500K
Modeled next size est.range $500K$800K
0.1×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Alain Castro1 other2018-12
Sanjay Arora1 other2018-12
Argelia Lachance2018-12
John White, Jr.2018-12
Robert DiMarco2018-12
Registry & provenance

Boulder Botanicals & Biosciences Laboratories, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1762755
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Nalu Bio, Inc.Biotech / PharmaSeries A$4.8M$48.4Msame sector · same stage
Los Angeles Biosciences, Inc.Biotech / PharmaSeries A$4.9M$16.4Msame sector · same stage
Archean Biologics, Inc.Biotech / PharmaSeries A$4.5M$100.7Msame sector · same stage
BroadOak Biolog, LLCBiotech / PharmaSeries A$5.0M$19.8Msame sector · same stage
Jitai Biological Technology LtdBiotech / PharmaSeries A$5.0M$11.7Msame sector · same stage
Wasser Bio Environment Co.LtdBiotech / PharmaSeries A$5.0M$16.4Msame sector · same stage
Caladan Bio Inc.Biotech / PharmaSeries A$5.1M$32.2Msame sector · same stage
Definitive Biotechnologies LLCBiotech / PharmaSeries A$5.2M$8.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Pillar Biosciences Inc.Biotech / PharmaSeries B$511.7M83%
Curve Biosciences, Inc.Biotech / PharmaSeries B$134.0M82%
Me Biosciences, Inc.Biotech / PharmaPre-Seed$25.6M82%
Life Biosciences LLCBiotech / PharmaSeries C$2.8B81%
Boulder Organics LLCAgtech / FoodtechSeries A$17.5M81%
Ruby Bio, Inc.Biotech / PharmaSeries A$27.7M81%
Animal Biosciences, Inc.Biotech / PharmaSeed$31.6M81%
PharmaCann Inc.Biotech / PharmaSeries D+$413.5M81%
Frequently asked
How much funding has Boulder Botanicals & Biosciences Laboratories, Inc. raised?
Boulder Botanicals & Biosciences Laboratories, Inc. has raised approximately $4.7M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Boulder Botanicals & Biosciences Laboratories, Inc.'s estimated valuation?
Provath's modeled valuation for Boulder Botanicals & Biosciences Laboratories, Inc. is approximately $16.8M (modeled range $559K–$91.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Boulder Botanicals & Biosciences Laboratories, Inc. at?
Boulder Botanicals & Biosciences Laboratories, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Feb 15.
What does Boulder Botanicals & Biosciences Laboratories, Inc. do and where is it based?
Boulder Botanicals & Biosciences Laboratories, Inc. operates in the Biotech / Pharma sector, based in GOLDEN.
Explore related

See where Boulder Botanicals & Biosciences Laboratories, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Boulder Botanicals & Biosciences Laboratories, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.